UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 29, 2019
LABORATORY CORPORATION OF AMERICA HOLDINGS
(Exact name of registrant as specified in Charter)
| Delaware | 1-11353 | 13-3757370 | ||
| (State or other jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| 358 South Main Street, Burlington, North Carolina |
27215 | |
| (Address of principal executive offices) | (Zip Code) |
336-229-1127
Registrant’s telephone number, including area code
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
| Common Stock, $0.10 par value | LH | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 7.01 | Regulation FD Disclosure. |
LabCorp® (NYSE: LH), a leading global life sciences company, today announced that director Peter M. Neupert has been elected to serve as Lead Independent Director of the Board of Directors, effective July 10, 2019. Mr. Neupert, 63, has served as a director of LabCorp since January 2013, and currently serves on the Audit Committee as an audit committee financial expert and as Chair of the Nominating and Corporate Governance Committee.
As previously described in LabCorp’s Form 8-K filed on June 5, 2019, Adam H. Schechter ceased serving as LabCorp’s Lead Independent Director effective June 4, 2019 in connection with his appointment to the position of President and Chief Executive Officer of LabCorp effective November 1, 2019.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant
| By: | /s/ Sandra van der Vaart | |
| Sandra van der Vaart | ||
| Global General Counsel and Corporate Secretary | ||
July 29, 2019